AstraZeneca's Koselugo Approved in EU for NF1

TL;DR

EU approves AstraZeneca's Koselugo for kids with NF1 tumors.

AI Summary

AstraZeneca PLC announced on October 28, 2025, that Koselugo (selumeticinib) has received approval in the European Union. This approval is for the treatment of pediatric patients aged two years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

Why It Matters

This EU approval expands access to a crucial treatment for children with NF1 and plexiform neurofibromas, potentially improving their quality of life.

Risk Assessment

Risk Level: low — This is a routine regulatory filing announcing an approval, not a significant financial event.

Key Players & Entities

• AstraZeneca PLC (company) — Registrant
• Koselugo (selumeticinib) (drug) — Approved medication
• European Union (location) — Approval jurisdiction
• October 28, 2025 (date) — Filing date
• neurofibromatosis type 1 (NF1) (medical_condition) — Indication for treatment
• pediatric patients (demographic) — Target patient group

FAQ

From the Filing

0001654954-25-012262.txt : 20251028 0001654954-25-012262.hdr.sgml : 20251028 20251028080256 ACCESSION NUMBER: 0001654954-25-012262 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251028 FILED AS OF DATE: 20251028 DATE AS OF CHANGE: 20251028 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251421489 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a0174f.htm KOSELUGO (SELUMETINIB) APPROVED IN THE EU a0174f FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of October 2025   Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________       AstraZeneca PLC   INDEX TO EXHIBITS     1. Koselugo (selumetinib) approved in the EU     28 October 2025   Koselugo   approved in the EU   for plexiform neurofibromas in adults with neurofibromatosis type 1   Approval based on KOMET Phase III trial results which showed 20% objective response rate in tumour size reduction   Alexion, AstraZeneca Rare Disease's  Koselugo  (selumetinib), an oral, selective MEK inhibitor, has been approved in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult patients with neurofibromatosis type 1 (NF1). 1   The approval by the European Commission follows the  positive opinion  of the Committee for Medicinal Products for Human Use (CHMP) and is based on results from KOMET, the largest and only placebo-controlled global Phase III trial in this patient population, which were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in  The Lancet . 2   NF1 is a rare, progressive, genetic condition usually diagnosed in early childhood, but often progressing into adulthood, that can impact every organ system. 3,4  Up to 50% of people living with NF1 may develop a type of non-malignant tumour called PN that may affect the brain, spinal cord and nerves. 4,5  PN may appear later in a person's life and can grow and become large, leading to pain, disfigurement and muscle weakness, among other debilitating symptoms. 4,5   Prof. Pierre Wolk